Recent investigations have centered on the intersection of GLP|GIP|glucagon receptor activator therapies and dopaminergic communication. While GCGR agonists are increasingly employed for managing type 2 diabetes, their emerging impacts on motivation circuits, specifically influenced by dopaminerg